Adenovirus

According to a recent United Nations study, HIV infection rates among high-risk groups such as gays, drug users and sex workers are on the rise around the world.

A booster shot appears to improve tuberculosis (TB) resistance in previously vaccinated adults, according to new research in South Africa.

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced the initiation of a multi-center Phase 2 clinical trial designed to evaluate CMX001 in stem cell transplant recipients who are seropositive for cytomegalovirus (CMV).

Longhorn Vaccines & Diagnostics today announced it has been granted Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Longhorn Influenza A/H1N1-09 Prime RRT-PCR Assay™ in CLIA high complexity laboratories. . The Longhorn Influenza A/H1N1-09 Prime RRT-PCR Assay™ is a ready-use assay that requires no mixing prior to use and has been authorized for use on the ABI 7500.

Bioheart, Inc., announced today that the company has commenced work on its REGEN trial, a Phase I Clinical Trial to test genetically modified MyoCell® in patients suffering from Congestive Heart Failure (CHF). Bioheart’s MyoCell® is a regenerative cell therapy that uses myoblasts, or muscle stem cells,that are grown from a patient’s own muscle. MyoCell® has been tested successfully on patients in four clinical trials.

Reportlinker.com announces that a new market research report is available in its catalogue: HIV/AIDS Testing - World Review

Biologics contract manufacturer Omnia Biologics, Inc. (Omnia) (Rockville, MD) and biologics manufacturing and process development consultants Biotech Experts, Inc. (Clarksburg, MD) today announced a deal for manufacturing and process development services.

Cell Medica, a clinical stage cellular therapeutics company engaged in the development and delivery of cellular immunotherapy treatment strategies for infectious disease and cancer, has announced that is has appointed four key staff to drive forwards the Company’s activities in the commercialisation of cell therapy treatments.

Research and Markets (http://www.researchandmarkets.com/research/7035ab/infectious_disease) has announced the addition of the "Infectious Disease Testing Market: US, Europe, Japan--Emerging Opportunities and Business Strategies" report to their offering.